Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive SBRT with MR-detected Nodule Boost for High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT05628363Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2023
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial in prostate cancer (PCa), sponsored by Washington University School of Medicine. Primary endpoint: Acute CTCAEv5 grade >=3 genitourinary (GU) or gastrointestinal (GI) adverse event. Started Jan 2023; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05628363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628363.